LFTD PARTNERS INC.

LIFD ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2012
Revenue $36.9M $37.3M $51.6M $57.4M $31.7M $5.3M $0 $250.4K
Cost of Revenue $24.3M $24.6M $31.9M $36.4M $15.7M $3.4M $0
Gross Profit $12.6M $12.8M $19.7M $21.0M $15.9M $1.9M $0 $-26.7K
Gross Margin 34.2% 34.2% 38.2% 36.6% 50.4% 36.2% -10.7%
Operating Expenses
Research & Development $19.8K $19.8K
SG&A Expense $134.0K $58.5K $832.5K
Operating Income $913.2K $-773.5K $2.4M $9.8M $7.8M $-1.5M $-1.3M $-1.2M
Operating Margin 2.5% -2.1% 4.7% 17.1% 24.6% -28.4% -497.9%
Interest Expense $110.5K $120.2K $142.4K $65.2K $28.0K $153.4K
Pretax Income $-24.4M $-2.4M $2.8M $10.0M $7.2M $-1.5M $0
Income Tax Expense $432.8K $-524.4K $598.1K $-2.8M $1.4M $0 $-1.2M
Net Income $-24.9M $-1.9M $2.2M $7.2M $5.8M $-1.5M $-1.2M $-2.4M
Net Margin -67.3% -5.0% 4.2% 12.5% 18.3% -28.7% -944.1%
EPS (Basic) $-1.68 $-0.13 $0.15 $0.51 $0.50 $-0.15 $-0.12 $-0.22
EPS (Diluted) $-1.68 $-0.13 $0.13 $0.45 $0.43 $-0.15 $-0.12 $-0.22
Shares Outstanding (Basic) 14.8M 14.8M 14.6M 14.1M 11.4M 11.9M 10.3M
Shares Outstanding (Diluted) 14.8M 14.8M 16.4M 15.9M 13.4M 11.9M 10.3M 11.0M
Dividends Per Share
← Newer Page 1 of 2 Older →